title: Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales.
authors.affiliation: Cancer Screening Evaluation Unit, Institute of Cancer Research, Sutton, Surrey.
authors.forename: J
authors.initials: J
authors.lastname: Chamberlain
authors.forename: J
authors.initials: J
authors.lastname: Melia
authors.forename: S
authors.initials: S
authors.lastname: Moss
authors.forename: J
authors.initials: J
authors.lastname: Brown
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D017048:Health Care Costs; D006760:Hospitalization; D006801:Humans; D015994:Incidence; D008297:Male; D008403:Mass Screening / Q000191:economics / Q000379:methods; D008875:Middle Aged; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000191:economics / Q000401:mortality / Q000628:therapy; D012017:Referral and Consultation; D012307:Risk Factors; D016526:Workload
chemical_list: D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen